Allothera

Problem​

Neuropathic pain affects a large patient population and remains poorly treated: current options such as pregabalin, gabapentinoids, antidepressants, lidocaine/​capsaicin, and opioids often deliver limited relief, while causing sedation, dizziness, burning, addiction risk, or other side effects. The core issue is that today’s standard of care mostly dampens pain transmission rather than addressing the underlying peripheral sensitization that drives touch-evoked pain.

Solution​

Allothera’s solution is to inhibit STOML3, a peripheral mechanotransduction regulator that amplifies mechanosensitive channel activity and drives pathological mechanical hypersensitivity. The lead program has already shown strong preclinical and translational validation: STOML3 antagonists reverse mechanically evoked currents in sensory models, reduce pain behavior in animal models, and have evidence of activity in human iPSC-derived sensory neurons, supporting both therapeutic and biomarker-guided patient stratification potential.

Looking For

• Investors
• Partners

News and Background